AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02957734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation of severely worn dentitions
Description: Patients with severely worn dentition and functional problems are included in this study. Teeth are rehabilitated using indirect composite resin restorations in an increased vertical dimension of occlusion in order to optimize function and esthetics.
Study NCT00195039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
Description: Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min.
Study NCT00874393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion Placebo
Description: Dextrose (D5W)
Study NCT00874393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syringe Placebo
Description: Normal saline
Study NCT00874393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syringe Placebo
Description: Normal saline
Study NCT01855672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of the Occipital Nerves
Description: Electrical stimulation of the occipital nerves.
Study NCT00312546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90 mg subcutaneously twice daily
Study NCT00312546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: 500 to 750 mg, taken orally twice daily
Study NCT03850847 — intervention group
Intervention type: OTHER
Intervention: Step 1: Semi-structured Interviews
Description: 1. Cover SDMs' experience around:~   * withdrawal of life sustaining therapies~  * organ donation among those who were approached (including with the medical team and the organ donation organisation)~  * understanding of the situation~  * views on any gaps in the quantity or quality of information and discussion they received concerning their loved one's end-of-life care or donation process~2. Explore factors they perceived to influence their decision to consent to organ donation or not (or that would have influenced their decision for those not approached), and how such factors may have changed over the course of making this decision and since the decision (or since the event for those not approached).
Study NCT03850847 — intervention group
Intervention type: OTHER
Intervention: Step 2: National Telephone Survey
Description: Explore SDM's beliefs and experiences around end of life and assess which beliefs are associated with the decision taken at the end of life, including decision to donate organs or not (and the strength of this association)
Study NCT02287571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derotation splint
Description: This group is the actual intervention group.
Study NCT02287571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: elastic bandage
Description: This group is the routine treatment (control) valid in the clinical practice.
Study NCT02707302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iodophor-impregnated adhesive drapes group
Description: Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.
Study NCT02707302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iodophor-free adhesive drapes group
Description: Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
Study NCT04168450 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: WiSAT System, Passive Feedback
Description: The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.
Study NCT04168450 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: WiSAT System, Active Feedback
Description: The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
Study NCT00003996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00003996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT00003996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00003996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00003996 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01599221 — intervention group
Intervention type: DEVICE
Intervention: EBA2
Description: Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
Study NCT02015728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.
Study NCT02015728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is a broad-spectrum kinase inhibitor.
Study NCT02015728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is an mTOR pathway inhibitor.
Study NCT02015728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
Study NCT02015728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib is a broad spectrum SRC inhibitor.
Study NCT00980252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
Study NCT04032015 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Device used to administer electromagnetic fields to the brain to alter connectivity patterns
Study NCT04032015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Device used to administer electromagnetic fields to the brain to alter connectivity patterns
Study NCT03304405 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gait Analysis
Description: All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
Study NCT00995917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin K acupoint injection
Description: Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.
Study NCT00995917 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline Injection
Description: Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.
Study NCT02950909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static exercise for emphasized neck extensors
Description: Emphasized activation of the deep neck extensors was searched for applying a localized resistance with the thumb and index finger at the level of the vertebral arch of C4 while pushing into flexion in a ventral-cranial direction, approximately parallel to the surface of the zygapophyseal joint, asking the patient to resist maximally during 6 seconds in sitting position
Study NCT02950909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic exercise for emphasized neck extensors
Description: The patient was asked to fix his gaze at an object lying between both elbows hoping to in order to emphasize extension in the lower cervical spine and consequently activation of the extensors in this region.
Study NCT02950909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static exercise for general neck extensors
Description: Emphasized activation of all neck extensors was searched for applying the resistance with the therapist's hand or a wall respectively a towel at the occiput in sitting position
Study NCT02950909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic exercise for general neck extensors
Description: . The patient was asked to fix his gaze at an object lying between both hands. Extension consequently occurred in the entire cervical spine.
Study NCT04146350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV+/-Cat
Description: pars plana vitrectomy+/-cataract
Study NCT04146350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV+/-Cat+Gas
Description: pars plana vitrectomy+/-cataract+gas tamponade
Study NCT04146350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV+ILM+/-Cat+/-Gas
Description: pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-gas tamponade
Study NCT04146350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV+ILM+/-Cat+/-Oil
Description: pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade
Study NCT04146350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PSR
Description: posterior scleral reinforcement
Study NCT04146350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）
Description: posterior scleral reinforcement+pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade (or gas)
Study NCT04146350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gas
Description: gas tamponade alone
Study NCT01407666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral blocks
Description: use bilateral thoracic paravertebral blocks for pain control
Study NCT00795236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
Study NCT00465088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin ER/Simvastatin Tablets
Description: Up to 2000 mg/40 mg at bedtime
Study NCT00465088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 40 mg at bedtime
Study NCT03142984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic Products
Description: Phase 1:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)
Study NCT01005498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate - high fat diet
Description: The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
Study NCT01005498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate - low fat diet
Description: The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
Study NCT00226811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
Study NCT03468361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Product Petroselinum crispum (Parsley)
Description: Parsley herb, in fresh form will be obtained from the local market available. The herb will be properly washed with distilled water and dried properly for 10 to 15 days under shade in the lab. Soft gelatin capsules will be filled with parsley powder (dried herb) in amount normally recommended in daily routine (1g) will be administered to patients once daily.
Study NCT03468361 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gelatin capsules will be filled with 1 gram of lactose (inert pharmaceutical ingredient) and will be administered to patients once daily.
Study NCT03507205 — intervention group
Intervention type: DEVICE
Intervention: Biomatrix; Biomatrix Flex; Nobori
Description: Biodegradable polymer-coated biolimus-eluting stents
Study NCT02312245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02312245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02312245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02312245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT02312245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT06034444 — intervention group
Intervention type: OTHER
Intervention: interRAI LTCF
Description: Standardized evaluations (interRAI LTCF) will be introduced to selected nursing homes in Quebec.
Study NCT02367248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deferoxamine
Description: Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
Study NCT02367248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xingnaojing injection
Description: Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
Study NCT02367248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
Study NCT01346722 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet-ZnBfR
Description: zinc biofortified rice-based diet
Study NCT01346722 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet- CR
Description: conventional rice-based diet
Study NCT01346722 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CR + Zn
Description: conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
Study NCT01768585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Please see description of Intervention Arm
Study NCT01768585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02571959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and clavulanic acid
Description: Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
Study NCT02571959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and clavulanic acid
Description: Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
Study NCT01354080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage based on the tensegrity rule
Description: The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
Study NCT01354080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: massage - classical abdominal
Description: The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
Study NCT01249144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular Lens (IOL)
Description: Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
Study NCT02026583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study NCT01720407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod cream + surgery
Description: Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
Study NCT01720407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + surgery
Description: Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
Study NCT01794351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol
Description: In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
Study NCT01794351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
Study NCT02978040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age > 75 years old).
Study NCT02978040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age > 75 years old) .
Study NCT02978040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight \< 60 kg or age > 75 years old).
Study NCT01217645 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 150 mg [14C] AZD6765
Study NCT03430362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine N Butylbromide
Description: 7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
Study NCT03430362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: Group B, will receive 2 ml of normal saline single intravenous dose
Study NCT01150305 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: Peripheral whole blood sample, 5 ml
Study NCT04430140 — intervention group
Intervention type: DEVICE
Intervention: CT Scan
Description: CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)\*: 0.6
Study NCT02836795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)
Description: humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Study NCT02675660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Homoarginine
Description: 125 mg L-homoarginine once daily
Study NCT01490047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
Study NCT03507205 — intervention group
Intervention type: DEVICE
Intervention: Xience Prime
Description: Durable polymer-coated everolimus-eluting stents